ARA 290
unknown riskAlso: Cibinetide · ARA290 · ERY290
ARA 290 is a non-hematopoietic analog of erythropoietin engineered to activate tissue-protective but not erythropoiesis pathways. It has Orphan Drug designation for sarcoidosis-associated neuropathy and has demonstrated efficacy in diabetic neuropathy trials.
Reported Benefits
Diabetic Neuropathy
Phase 2 trial showed improved nerve fiber density and pain scores in T2DM patients.
Sarcoidosis Neuropathy
Randomized trial demonstrated improved corneal nerve fiber density and pain.
Anti-inflammatory
Activates anti-inflammatory innate repair receptor (IRR) complex.
Mechanism of Action
ARA 290 was engineered by removing the erythropoiesis-stimulating receptor-binding residues from erythropoietin while retaining the tissue-protective signaling domain. It activates the innate repair receptor (IRR) — a heterodimer of EPOR and beta-c — which mediates anti-inflammatory, anti-apoptotic, and neuroprotective signaling.
Key Clinical Studies
Brines M et al. (2014)
RCT · 40 diabetic patients
Improved corneal nerve fiber density after 28 days
Heij L et al. (2012)
Phase 2 RCT · Sarcoidosis patients
Improved corneal nerve fiber density in sarcoidosis
Overview
ARA 290 represents a clever approach to drug development: taking erythropoietin (EPO) — a well-characterized protein hormone with powerful tissue-protective properties — and engineering away the hematopoietic (red blood cell stimulating) activity while preserving the protective signaling. This eliminates EPO’s significant cardiovascular risks in non-anemic patients.
The Two Faces of Erythropoietin
Native EPO has two receptor binding sites: one that activates EPOR homodimers (causing erythropoiesis and the associated thrombosis risk), and one that activates the IRR heterodimer (tissue protection). ARA 290 selectively activates only the IRR pathway — a mechanistic refinement that took years to characterize.
Neuropathy Evidence
The diabetic and sarcoidosis neuropathy data is meaningful. Corneal confocal microscopy — measuring small nerve fiber density in the cornea as a proxy for systemic small fiber neuropathy — showed objective improvements in nerve fiber density, not just patient-reported pain scores. This objective endpoint strengthens the evidence quality.
Development Status
ARA 290 holds Orphan Drug designation for sarcoidosis neuropathy and has completed Phase 2 trials. Regulatory approval pathway remains active but uncertain as of 2025.
Regulatory Status
Research OnlyOrphan drug designation for sarcoidosis neuropathy; Phase 2 complete; no approval
Safety Profile
Side Effects
- •Injection site reactions (mild)
- •No hematopoietic effects by design
Contraindications
- •None established
Drug Interactions
- •None established
Primary Uses
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe ARA 290?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →